Medical treatment of behavioral manifestations of Huntington disease
- PMID: 28947111
- DOI: 10.1016/B978-0-12-801893-4.00011-0
Medical treatment of behavioral manifestations of Huntington disease
Abstract
Almost all patients with Huntington disease (HD) show some form of behavioral changes during the disease progression. These behavioral manifestations may already be present before cognitive or motor symptoms become apparent, and vary from subtle anxiety to severe psychosis and suicide attempts. These behavioral manifestations are related to both psychologic factors, like the burden of having a severe disease, and biologic factors that are related to the disease itself. In this chapter, both nonpharmacologic and pharmacologic interventions are discussed. Common treatment guidelines give guidance to the treatment of symptoms like depression, anxiety, and psychosis, but for more disease-specific symptoms like apathy, irritability, and obsessive-compulsive behaviors, off-label use of psychotropic medication seems to be inevitable since evidence for all interventions in HD is limited. Type and dosage of medication often depend on comorbidity, side-effects, and the use of other drugs, and because of the neurodegenerative nature of the disease, it is necessary to monitor patients clinically at a regular interval and adjust drugs accordingly as the disease progresses.
Keywords: anxiety; apathy; behavior; depression; irritability; obsessive-compulsive behaviors; psychiatric; psychosis; psychotropics.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
Nonmotor Symptoms in Huntington Disease.Int Rev Neurobiol. 2017;134:1397-1408. doi: 10.1016/bs.irn.2017.05.004. Epub 2017 Jun 1. Int Rev Neurobiol. 2017. PMID: 28805577 Review.
-
Short-term effects of olanzapine in Huntington disease.Neuropsychiatry Neuropsychol Behav Neurol. 2001 Jan;14(1):69-72. Neuropsychiatry Neuropsychol Behav Neurol. 2001. PMID: 11234911
-
Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY).J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1411-8. doi: 10.1136/jnnp-2013-307343. Epub 2014 May 14. J Neurol Neurosurg Psychiatry. 2014. PMID: 24828898
-
Psychopathology in verified Huntington's disease gene carriers.J Neuropsychiatry Clin Neurosci. 2007 Fall;19(4):441-8. doi: 10.1176/jnp.2007.19.4.441. J Neuropsychiatry Clin Neurosci. 2007. PMID: 18070848 Review.
-
[Psychiatric symptoms of Huntington's disease].Nervenarzt. 2024 Sep;95(9):871-884. doi: 10.1007/s00115-024-01728-z. Epub 2024 Aug 30. Nervenarzt. 2024. PMID: 39212681 Free PMC article. Review. German.
Cited by
-
Irritability in Huntington's Disease.J Huntingtons Dis. 2020;9(2):107-113. doi: 10.3233/JHD-200397. J Huntingtons Dis. 2020. PMID: 32417789 Free PMC article. Review.
-
Advances in the Diagnosis and Management of Psychotic Symptoms in Neurodegenerative Diseases: A Narrative Review.J Geriatr Psychiatry Neurol. 2023 Nov;36(6):435-460. doi: 10.1177/08919887231164357. Epub 2023 Mar 20. J Geriatr Psychiatry Neurol. 2023. PMID: 36941085 Free PMC article. Review.
-
Mental health symptoms among those affected by Huntington's disease: A cross-sectional study.Brain Behav. 2023 Apr;13(4):e2954. doi: 10.1002/brb3.2954. Epub 2023 Mar 6. Brain Behav. 2023. PMID: 36880126 Free PMC article.
-
Pathomechanisms of behavioral abnormalities in Huntington disease: an update.J Neural Transm (Vienna). 2024 Sep;131(9):999-1012. doi: 10.1007/s00702-024-02794-y. Epub 2024 Jun 14. J Neural Transm (Vienna). 2024. PMID: 38874766 Review.
-
Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities.Antioxid Redox Signal. 2019 Apr 10;30(11):1450-1499. doi: 10.1089/ars.2017.7321. Epub 2018 May 4. Antioxid Redox Signal. 2019. PMID: 29634350 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical